What are the side effects of axitinib/axitinib?

Axitinib/Axitinib (Axitinib), as a targeted therapy, has shown good efficacy in clinical application, but it is also accompanied by a series of side effects, and the manifestations and severity of these side effects may vary in different patients.

In clinical studies, the most common side effects include diarrhea, high blood pressure, fatigue, dysphonia (speech disorder), nausea and vomiting, decreased appetite, and weight loss. Patients may also experience palmar-plantar dysesthesia syndrome, a condition characterized by rash and numbness on the palms and soles of the feet. Bleeding, hypothyroidism (low thyroid function), protein in the urine, cough, and constipation are also common side effects. These adverse effects may affect the patient's quality of life and therefore require close monitoring and management during treatment.

In addition, some post-marketing observational data show that axitinib may cause artery-related adverse events, including aneurysms, dissections, and ruptures. The development of these vascular diseases can be a serious risk for patients and requires vigilance during treatment.

Adverse effects such as hypertension, arterial thromboembolic events, and venous thromboembolic events have also been reported in the treatment of various types of renal cancer. Patients sometimes experience serious complications such as heart failure, gastrointestinal perforation, and fistula formation. Problems such as thyroid dysfunction, impaired wound healing, reversible posterior leukoencephalopathy syndrome, and proteinuria have also been documented. In addition, hepatotoxicity and liver damage are also one of the side effects that need to be paid attention to when using axitinib.

Because axitinib may cause major adverse cardiovascular events and embryo-fetal toxicity, more caution is required during treatment, especially in patients with a history of cardiovascular disease. Doctors usually conduct individualized monitoring and management based on the patient's specific situation to reduce the incidence of these side effects.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta